Orthocell granted Singapore patent for ‘CelGro’

Company News

by David Chau

Regenerative medicine company Orthocell Ltd (ASX:OCC) has received an additional Singapore patent for its CelGro medical device.

CelGro is collagen-based used for soft tissue regeneration.

The Singapore patent relates to the company’s method of manufacture of novel bio-scaffolds. These bio-scaffolds are used to aid in the surgical repair of soft tissue injuries such as tendon, nerve, cartilage and bone – as well as the delivery of stem cells to the relevant surgical sites.

In addition to Singapore, Orthocell has also been granted patents in the US, Canada, China and New Zealand.

This morning, Orthocell shares are tracking 1.27% higher at 40 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.